文献速递湿疹皮炎与荨麻疹

乌司奴单抗治疗日本重度特应性皮炎:随机双盲安慰剂对照II期研究

Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study.
PubMed 文献 · Br J Dermatol · 2017-06-27

该随机双盲安慰剂对照II期研究纳入79例日本重度或极重度特应性皮炎患者,按1:1:1随机接受乌司奴单抗45mg、90mg或安慰剂皮下注射(第0、4周),随访至24周。主要终点为第12周EASI评分较基线百分比变化,结果显示乌司奴单抗组与安慰剂组无显著差异,未显示有意义的疗效,但耐受性良好。

要点

  • 乌司奴单抗45mg和90mg治疗日本重度特应性皮炎未显示优于安慰剂的显著疗效。
  • 治疗总体耐受性良好,最常见不良事件为鼻咽炎和特应性皮炎加重。

核心结论

  • 乌司奴单抗45mg和90mg对日本重度特应性皮炎患者未显示有意义的疗效,但治疗总体耐受性良好。

研究设计与样本

  • 随机、双盲、安慰剂对照II期研究,纳入79例20-65岁日本重度或极重度特应性皮炎患者,按1:1:1随机分配至乌司奴单抗45mg组(n=24)、90mg组(n=28)或安慰剂组(n=27)。
  • 患者在第0周和第4周接受皮下注射,双盲治疗期12周,随访至第24周。
  • 主要疗效终点为第12周EASI评分较基线的百分比变化。

主要发现

  • 主要次要疗效终点(EASI 50、EASI 75、IGA 0-1、瘙痒评分变化、DLQI变化)在乌司奴单抗组与安慰剂组间亦无显著改善。
  • 最常见治疗中出现的不良事件为鼻咽炎和特应性皮炎加重,后者在安慰剂组发生率高于乌司奴单抗组。

临床怎么用

  • 对于日本重度特应性皮炎患者,乌司奴单抗45mg和90mg未显示优于安慰剂的疗效,不应作为该人群的常规选择。

局限性

  • 本研究仅纳入日本患者,样本量较小(共79例),结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ustekinumab, a fully human monoclonal antibody against interleukin-12/23, may potentially be effective for severe atopic dermatitis (AD) treatment. OBJECTIVES: To evaluate efficacy and safety of ustekinumab 45 mg and 90 mg in patients with severe AD. METHODS: In this randomized, placebo-controlled, phase II study, Japanese patients (aged 20-65 years) with severe or very severe AD entered a 12-week double-blind treatment period during which they received (1 : 1 : 1) ustekinumab 45 mg, 90 mg or placebo subcutaneous injections at weeks 0 and 4, with follow-up until week 24. The primary efficacy end point was percentage change from baseline in Eczema Area and Severity Index (EASI) score at week 12. Major secondary efficacy end points included the proportion of patients achieving EASI 50, EASI 75, Investigator's Global Assessment score 0-1, change from baseline Atopic Dermatitis Itch Scale and Dermatology Life Quality Index. RESULTS: A total of 79 patients were randomized [ustekinumab 45 mg (n = 24), 90 mg (n = 28), placebo (n = 27)]. Ustekinumab treatment showed nonsignificant improvement in least square mean change from baseline EASI score at week 12 [45 mg: -38·2%, 95% confidence interval (CI) -21·02-19·51; P < 0·94 and 90 mg: -39·8%, 95% CI -21·84-17·14; P < 0·81] vs. placebo (-37·5%). A nonsignificant improvement in major secondary efficacy end points was observed in both ustekinumab groups vs. placebo. The most common treatment-emergent adverse events were nasopharyngitis and worsened AD (higher in placebo vs. ustekinumab groups). CONCLUSIONS: Ustekinumab 45 mg and 90 mg did not demonstrate meaningful efficacy in Japanese patients with severe AD. The treatment was generally well tolerated.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Saeki H, Kabashima K, Tokura Y, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol. 2017. PMID: 28338223. doi:10.1111/bjd.15493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。